Objective: CFRD is the most frequent comorbidity in CF. One reason for the recommendation to use Insulin as first line treatment is the lack of data supporting the use of oral anti-diabetic drugs. Nevertheless around 10% of all patients with CFRD are treated with oral drugs. Method: We initiated a multi-centres trail (NCT 00662714), enrolling patients identified by screening for CFRD. In the study the effects of 3 daily insulin injections were compared to oral treatment with Repaglinide in a RCT over two years. The primary outcome parameter was HbA 1 c as a marker of glycaemic control. Secondary outcome parameters were change in pulmonary function (FEV 1 %pred) and change in BMI-Zscore. 73 patients with newly diagnosed CFRD were randomised. Age (mean±SD) 22.2±8.8 years, BMI-Z-score −0.74±1.1; HbA 1 c 6.5±0.8%; FEV 1 66.9±23.5%pred.
After 1 year of treatment, BMI-Z-score was better with insulin but this did not persist after two years. There was no inferiority of the oral treatment in neither the primary nor the secondary outcome parameter after two years of treatment.
Conclusion:
In this group of newly diagnosed patients with CFRD, the oral treatment with Repaglinide was a safe and effective therapeutic option. This is important because in this age group there are many challenges (e.g. start with a job) and the additional burden of insulin treatment might be postponed for at least two years. 
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WS16.3 Vitamin D supplementation in patients with cystic fibrosis:
A pilot randomized controlled trial 
Conclusion:
We have shown that the use of our treatment algorithm has significantly improved vitamin D levels in patients with insufficient or deficient vitamin D status. Our aim is to continue with this approach to ensure that vitamin D levels are maintained above 50 nmol/l throughout the patients' lifetime.
